Brianne Jahn - 29 Mar 2023 Form 4 Insider Report for LianBio (LIANY)

Reporting relationship: Chief Business Officer
Issuer ticker: LIANY
Reported as of: 29 Mar 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 31 Mar 2023, 16:21:39 UTC
Prior SEC filing: 24 Jan 2023
Next SEC filing: 18 Jun 2026
Source filing: View source filing
Reporting owner signature: By: /s/ Angela Chen, Attorney-in-Fact

Key filing fact

Brianne Jahn filed Form 4 for LianBio (LIANY) on 31 Mar 2023.

Key facts

This page summarizes Brianne Jahn's Form 4 filing for LianBio (LIANY).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 31 Mar 2023, 16:21.

Change

Previous filing in this sequence was filed on 24 Jan 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LIAN transaction

Ordinary Shares

Award

Transaction value: $0
Shares: +224,005
Change %
Price: $0.000000
Shares after: 224,005
Date: 29 Mar 2023
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents restricted share units granted to the Reporting Person under the LianBio 2021 Equity Incentive Plan. Each restricted share unit represents the contingent right to receive one share of the Issuer's Ordinary Shares. 25% of the restricted share units shall vest on March 29, 2024; the remainder shall vest in 25% annual installments such that the restricted share units are fully vested on March 29, 2027, subject to the Reporting Person providing continuous service to the Issuer on each such date.